Clinical view on pathomorphological risk factors after initial enucleation of the eye for retinoblastoma. Literature review
https://doi.org/10.21682/2311-1267-2025-12-2-90-95
Abstract
Retinoblastoma (RB) is the most common malignant tumor of the eye found in pediatric practice. Currently, in developed countries, the overall survival rate is approaching 100 % with a high rate of eye preservation up to 90 %, but such a treatment method as enucleation remains relevant today. The study of prognostic morphological factors in eyes removed after enucleation has been the subject of study for several decades in order to optimize adjuvant therapy. On the one hand, to intensify treatment to prevent relapse of RB, on the other hand, to refuse chemotherapy to avoid “overtreatment” of the patient.
Our article presents an analysis of the experience of different countries in determining morphological risk factors that influence the appointment of adjuvant chemotherapy after primary enucleation.
Supporting agencies: The study was performed without external funding
About the Authors
I. Yu. Trushkova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Pediatric Oncologist Department of Pediatric Bone Marrow and Hematopoietic Stem Cell Transplantation of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.
23 Kashirskoe Shosse, Moscow, 115522
T. L. Ushakova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Leading Researcher of the Children’s Oncology Department of Surgical Treatment Methods of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Professor at the Department of Pediatric Oncology named after Academician L.A. Durnov at Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia.
23 Kashirskoe Shosse, Moscow, 115522; Bldg. 1, 2/1 Barrikadnaya St., Moscow, 125993
E. A. Мoroz
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Pathologist, Senior Researcher of the Clinical Diagnostic Center Department of Morphological and Molecular Genetic Diagnostics of Tumors at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Associate Professor Department of Pathological Anatomy and Clinical Pathological Anatomy of the Institute of Human Biology and Pathology at N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia.
23 Kashirskoe Shosse, Moscow, 115522; 1 Ostrovityanova St., Moscow, 117997
References
1. Ушакова Т.Л., Павловская А.И., Поляков В.Г. Морфологические факторы прогноза у детей с односторонней ретинобластомой после инициальной энуклеации. Онкохирургия. 2011;3(4):4–8. doi: 10.1002/pbc.28963.
2. Ushakova T.L., Pavlovskaya A.I., Polyakov V.G. Morphological prognostic factors in children with unilateral retinoblastoma after initial enucleation. Onkokhirurgiya = Oncosurgery. 2011;3(4):4–8. (In Russ.).
3. Ushakova T.L. Modern approaches to the treatment of retinoblastoma. Bulletin of the Federal State Budgetary Institution “N.N. Blokhin Russian Cancer Scientific Center” = Journal of N.N. Blokhin Russian Cancer Research Center. 2011;22(3):41–8. (In Russ.).
4. Ushakova T.L. Risk-adapted therapy for retinoblastoma in children. Thesis of … Dr. of Sci. (Med.). M., 2012. P. 195. (In Russ.).
5. Sastre X., Chantada G.L., Doz F., Wilson M.W., de Davila M.T., Rodríguez-Galindo C., Chintagumpala M., Chévez-Barrios P.; International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199–202. doi: 10.5858/133.8.1199.
6. Kaliki S., Shields C.L., Cassoux N., Munier F.L., Chantada G., Grossniklaus H.E., Yoshikawa H., Fabian I.D., Berry J.L., McKenzie J.D., Kimani K., Reddy M.A., Parulekar M., Tanabe M., Furuta M., Grigorovski N., Chevez-Barrios P., Scanlan P., Eagle R.C. Jr, Rashid R., Coronado R.D., Sultana S., Staffieri S., Frenkel S.,
7. Suzuki S., Ushakova T.L., Ji X. Defining High-risk Retinoblastoma: A Multicenter Global Survey. JAMA Ophthalmol. 2022;140(1):30–6. doi: 10.1001/jamaophthalmol.2021.4732.
8. Chévez-Barrios P., Eagle R.C. Jr, Krailo M., Piao J., Albert D.M., Gao Y., Vemuganti G., Ali M.J., Khetan V., Honavar S.G., OʼBrien J., Leahey A.M., Matthay K., Meadows A., Chintagumpala M. Study of Unilateral Retinoblastoma With and Without Histopathologic HighRisk Features and the Role of Adjuvant Chemotherapy: A Childrenʼs Oncology Group Study. J Clin Oncol. 2019;37(31):2883–91. doi: 10.1200/JCO.18.01808.
9. Sreelakshmi K.V., Chandra A., Krishnakumar S., Natarajan V., Khetan V. Anterior Chamber Invasion in Retinoblastoma: Not an Indication for Adjuvant Chemotherapy. Invest Ophthalmol Vis Sci. 2017;58(11):4654–61. doi: 10.1167/iovs.17-22111.
Review
For citations:
Trushkova I.Yu., Ushakova T.L., Мoroz E.A. Clinical view on pathomorphological risk factors after initial enucleation of the eye for retinoblastoma. Literature review. Russian Journal of Pediatric Hematology and Oncology. 2025;12(2):90-95. (In Russ.) https://doi.org/10.21682/2311-1267-2025-12-2-90-95
Views:
10
Email this article 